Significant mucosal sIgA production after a single oral or parenteral administration using in vivo CD40 targeting in the chicken

Chou, Wen-Ko; Chen, Chang-Hsin; Vuong, Christine N.; Abi-Ghanem, Daad; Waghela, Suryakant D.; Mwangi, Waithaka; Bielke, Lisa R.; Hargis, Billy M.; Berghman, Luc

doi:10.1016/j.rvsc.2016.08.013

Cited by 14 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enhanced protection upon CpG ODN administration has also been reported for Marek's disease virus ( 34 ), as well as infection with Salmonella enterica ( 35 ) and Escherichia coli ( 36 ). Other potential immune stimulators include oligopeptides complexed with an agonistic anti-chicken CD40 monoclonal antibody ( 37 ) and the immune potentiator CVCVA5, which induces enhanced immune responses and protection against AIV upon vaccination ( 38 , 39 ).…”

Section: Mucosal Vaccination In Birdsmentioning

confidence: 99%

The Well-Developed Mucosal Immune Systems of Birds and Mammals Allow for Similar Approaches of Mucosal Vaccination in Both Types of Animals

et al. 2018

View full text Add to dashboard Cite

The mucosal immune system is a compartmentalized part of the immune system that provides local immunity in the mucosa of the respiratory, gastrointestinal, and digestive tracts. It possesses secondary lymphoid tissues, which contain immune cells, such as T, B, and dendritic cells. Once the cells of the mucosal immune system are stimulated by luminal antigens, including microorganisms, they infiltrate into diffuse areas of mucosal tissues (e.g., respiratory mucosa and lamina propria of intestinal villi) and exhibit immune effector functions. Inducing the antigen-specific immune responses in mucosal tissues by mucosal vaccination would be an ideal strategy for not only humans, but also mammals and birds, to protect against infectious diseases occurring in mucosal tissues (e.g., pneumonia and diarrhea). Infectious diseases cause huge economic losses in agriculture, such as livestock and poultry industries. Since most infectious diseases occur in mucosal tissues, vaccines that are capable of inducing immune responses in mucosal tissues are in high need. In this review, we discuss the current understanding of mucosal immunity in mammals and birds, and recent progress in the development of mucosal vaccines.

show abstract

Section: Mucosal Vaccination In Birdsmentioning

confidence: 99%

The Well-Developed Mucosal Immune Systems of Birds and Mammals Allow for Similar Approaches of Mucosal Vaccination in Both Types of Animals

et al. 2018

View full text Add to dashboard Cite

show abstract

“…On the contrary, the result from the aptamer RCA which consists of two DNA sequences from the aptamer library that were not enriched according to the Illumina sequencing result (Negative control) showed no activation of the cell line. Aptamer RCA II was also compared with the antichicken CD40 mAb (mAb 2C5) that was previously shown to stimulate the chicken HD11 cells 19 as the positive control (Fig. 2B).…”

Section: Rolling Circle Amplificationmentioning

confidence: 99%

“…In recent studies, our group demonstrated a novel anti-chCD40 mAb (designated mAb 2C5) has the ability to induce significant stimulation in chicken HD11 macrophage cell line. When this CD40 agonist was administered using different routes in combination with a desired antigenic peptide, the CD40-targeted immunogen induced robust immune response and several desired effects such as immunoglobulin class switching occured [17][18][19] . However, the high cost and difficulty for mAb production would make it impractical to commercialize this as a vaccine adjuvant.…”

mentioning

confidence: 99%

DNA aptamer-based rolling circle amplification product as a novel immunological adjuvant

Al-Ogaili

Liyanage

Lay

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

Several agonists to CD40 have shown to induce acquired immune responses. Here, we developed and evaluated the rolling circle amplification (RCA) products that are based on anti-CD40 DNA aptamers as a novel vaccine adjuvant. First, we developed DNA aptamers with specific binding affinity to chicken CD40 extra domain (chCD40ED). Next, we prepared the RCA products that consist of these aptamers to increase the spanning space and overall binding affinity to chCD40ED. Using 8 DNA aptamer candidates, 4 aptamer-based RCA products (aptamer RCAs) were generated, each consisting of two distinct aptamers. We demonstrated that all 4 aptamer RCAs significantly induced the signal transduction in chicken HD11 macrophage cell line (p < 0.05). Finally, we conjugated one of the aptamer RCAs (Aptamer RCA II) to M2e epitope peptide of influenza virus as a model hapten, and the immune complex was injected to chickens. Aptamer RCA II stimulated anti-M2e IgG antibody production to the level significantly higher as compared to the control (M2e epitope alone; p < 0.05). The results of our work suggest that aptamer RCA is a novel platform to boost the efficacy of vaccines, which might find broad applications to other antigens beyond M2e epitope evaluated in this study using chicken infection model.

show abstract

“…SIgA is formed by the combination of pIgR, J-chain and α-chain (IgA) and is mainly secreted by mature plasma cells in small intestinal mucosa. The secretion of SIgA on small intestinal mucosa plays a leading role in maintaining intestinal homeostasis and the balance of immune system [5].…”

Section: Introductionmentioning

confidence: 99%

Effect of Peptides from Alaska Pollock on Intestinal Mucosal Immunity Function and Purification of Active Fragments

2019

View full text Add to dashboard Cite

The intestinal mucosal barrier plays an important role in systemic immune functions. This study aimed to find the mechanism of peptide from Alaska Pollock (APP) on intestinal mucosal immunity in mice induced by cyclophosphamide (Cy). Cy-induced decreases of body weight and index of immune organ were significantly improved by APP as compared with Cy group (p < 0.05). APP could promote the secretion of SIgA and IgA on intestinal mucosa (p < 0.05) and mainly had an impact on the final differentiation of IgA+ B cell, thereby promoting the secretion of plasma cells, which can be corroborated by the increases of IL-6 and IL-10 (p < 0.05). APP with high immune activity was separated and two peptides were purified and identified as Gly–Val–Ile–Lys and Ala–Cys–Asn–Gly–Arg. Therefore, APP can be considered as beneficial ingredients to protect the intestinal barrier disruption induced by Cy.

show abstract

Significant mucosal sIgA production after a single oral or parenteral administration using in vivo CD40 targeting in the chicken

Cited by 14 publications

References 20 publications

The Well-Developed Mucosal Immune Systems of Birds and Mammals Allow for Similar Approaches of Mucosal Vaccination in Both Types of Animals

The Well-Developed Mucosal Immune Systems of Birds and Mammals Allow for Similar Approaches of Mucosal Vaccination in Both Types of Animals

DNA aptamer-based rolling circle amplification product as a novel immunological adjuvant

Effect of Peptides from Alaska Pollock on Intestinal Mucosal Immunity Function and Purification of Active Fragments

Contact Info

Product

Resources

About